NCT05114668View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

November 4, 2024

Study Completion Date

November 22, 2024

Conditions
Solid Tumor, Adult
Interventions
DRUG

EVT801

"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."

Trial Locations (2)

31059

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse

69373

Centre Léon Bérard, Lyon

Sponsors
All Listed Sponsors
lead

Kazia Therapeutics Limited

INDUSTRY